Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.57 |
| ▸ | RET | P07949 | 3/20 | 0.57 |
| ▸ | FLT3 | P36888 | 3/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.57 |
| ▸ | PLK4 | O00444 | 2/20 | 0.57 |
| ▸ | PLK1 | P53350 | 2/20 | 0.57 |
| ▸ | LTK | P29376 | 2/20 | 0.57 |
| ▸ | JAK3 | P52333 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205080 | 1.00 | MAPT (0.65) | MAPTALDH1A1SMN1; SMN2NPSR1KDM4E | |
| SCHEMBL2261891 | 0.82 | SMN1; SMN2 (0.68) | MAPTALDH1A1SMN1; SMN2NPSR1KDM4E | |
| SCHEMBL2261888 | 0.82 | SMN1; SMN2 (0.68) | MAPTALDH1A1SMN1; SMN2NPSR1KDM4E | |
| SCHEMBL3909749 | 0.82 | MAPT (0.69) | MAPTALDH1A1SMN1; SMN2NPSR1KDM4E | |
| SCHEMBL12364014 | 0.82 | SMN1; SMN2 (0.68) | MAPTALDH1A1SMN1; SMN2NPSR1KDM4E | |
| SCHEMBL3576657 | 0.82 | MAPT (0.69) | MAPTALDH1A1SMN1; SMN2NPSR1KDM4E | |
| SCHEMBL21837129 | 0.80 | EPHX2 (0.65) | MAPTALDH1A1SMN1; SMN2NPSR1KDM4E | |
| SCHEMBL11892099 | 0.79 | SMN1; SMN2 (1.00) | MAPTALDH1A1SMN1; SMN2NPSR1KDM4E | |
| SCHEMBL247890 | 0.79 | PDGFRB (0.76) | MAPTALDH1A1SMN1; SMN2NPSR1PKM | |
| SCHEMBL1301398 | 0.79 | PDGFRB (0.76) | MAPTALDH1A1SMN1; SMN2NPSR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450295-B2 | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | Acclaim BioMed USA LLC (US) | 2019-10-22 | — | — | US | disclosed |
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | Acclaim BioMed USA LLC (US) | 2015-02-12 | — | — | US | disclosed |
| US-7981880-B2 | 3-(aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | MMP1, HES1, COLGALT1 | MAPT 4019/4885ALDH1A1 616/4885SMN1; SMN2 4865/4885 |
| US-10450295-B2 | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | MMP1, HES1, COLGALT1 | MAPT 4019/4885ALDH1A1 616/4885SMN1; SMN2 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.